ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 0264 • ACR Convergence 2020

    Prevalence and Risk Factors Associated with Isolated Neutropenia in Outpatients with Systemic Lupus Erythematosus

    Nouf Alhammadi1, Murray Urowitz2 and Dafna Gladman3, 1University of Toronto, Toronto, Canada, 2University Health Network, University of Toronto, Toronto, ON, Canada, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Leukopenia in SLE is defined as leukocyte count below 4,000/mm3 on two or more occasions according to the ACR criteria and may include a…
  • Abstract Number: 0635 • ACR Convergence 2020

    Hydroxychloroquine Is Not Associated with Reduced Influenza Admissions in Rheumatoid Arthritis Patients

    Bonnia Liu1, Victor Yang2, Christopher McMaster3, Russell Buchanan4, Albert Frauman5 and David Liew6, 1Austin Health, Heidelberg, Victoria, Australia, Macleod, Victoria, Australia, 2Austin Health, Heidelberg, Victoria, Australia, Glen Waverley, Victoria, Australia, 3Austin Health, Melbourne, Victoria, Australia, Pascoe Vale South, Victoria, Australia, 4Austin Health, Melbourne, Victoria, Australia, Heidelberg, Melbourne, Victoria, Australia, 5Austin Health, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, 6Austin Health, Melbourne, Victoria, Australia, Heidelberg, Victoria, Australia

    Background/Purpose: Hydroxychloroquine (HCQ) is commonly used as a disease-modifying anti-rheumatic drug (DMARD) for patients with rheumatoid arthritis (RA). HCQ has previously been the subject of…
  • Abstract Number: 1620 • ACR Convergence 2020

    Hepatitis B Screening Practices When Prescribing Tocilizumab or Tofacitinib in Real World Practice

    Naomi Serling-Boyd1, Amir Mohareb2, Arthur Kim2, Emily Hyle2 and Zachary Wallace3, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital, Newton, MA

    Background/Purpose: Hepatitis B virus (HBV) reactivation can complicate treatment with immunosuppressive medications. Reactivation risk varies by the status of HBV infection but has been reported…
  • Abstract Number: 0430 • ACR Convergence 2020

    Outcomes of Coronavirus Disease 2019 Infection Among Patients Living with Rheumatic Diseases: A Matched Cohort Study from a US Multi-Center Research Network

    Kristin D'Silva1, April Jorge1, Na Lu2, Yuqing Zhang3, Zachary Wallace4 and Hyon Choi5, 1Massachusetts General Hospital, Boston, MA, 2Arthritis Research Canada, Vancouver, BC, Canada, 3Massachusetts General Hospital, Quincy, MA, 4Massachusetts General Hospital, Newton, MA, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA

    Background/Purpose: Whether patients living with systemic autoimmune rheumatic diseases (SARDs) suffer from more severe complications of Coronavirus Disease 2019 (COVID-19) infection remains unknown.Methods: We conducted…
  • Abstract Number: 0637 • ACR Convergence 2020

    Clinical and Treatment Features of Rheumatoid Arthritis in HIV-Infected Individuals Followed Longitudinally over Time

    Benjamin Naovarat1, Francis Williams1 and John Reveille2, 1The University of Texas McGovern Medical School, Houston, TX, 2Department of Internal Medicine, University of Texas, Houston, TX

    Background/Purpose: With the successful treatment of HIV-1 infection with combination anti-retroviral treatment, immune-mediated diseases that were rarely encountered in HIV positive individuals in the pre-treatment…
  • Abstract Number: 1623 • ACR Convergence 2020

    Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol

    Elena Joerns1, Bonnie Bermas2, Puneet Bajaj3, Nagendra Pokala1, Reuben Arasaratnam4, Joan Reisch1 and Dan (Clarie) Wang1, 1University of Texas Southwestern Medical Center, Dallas, TX, 2UTSouthwestern.edu, Dallas, TX, 3UT Southwestern, Dallas, TX, 4UT Southwestern Medical Center, Dallas, TX

    Background/Purpose: Rheumatology patients are particularly vulnerable to pneumococcal infection due to both their underlying disease and immunosuppressive therapy. Thus, quality improvement metrics include increasing pneumococcal…
  • Abstract Number: 0452 • ACR Convergence 2020

    Recombinant Zoster Vaccine in Patients with Rheumatic Diseases: A Retrospective Study of 622 Patients

    Tiphaine Lenfant1, Elizabeth Kirchner2, Rula Hajj-ali3, Leonard Calabrese3 and Cassandra Calabrese3, 1Cleveland Clinic Foundation, Rocky River, OH, 2Cleveland Clinic Foundation, Cleveland, 3Cleveland Clinic, Cleveland, OH

    Background/Purpose: The recombinant herpes zoster vaccine (RZV) was FDA-approved in 2017 but patients with rheumatic diseases were excluded from initial pivotal trials because of theoretical…
  • Abstract Number: 0642 • ACR Convergence 2020

    COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies

    Marta González Fernández1, Orlando Pompei fernández2, Joaquín María Belzunegui Otano3, Paula García Escudero1, Claudia Stoye2, Juan Ramón De Dios2, Belén Álvarez Rodríguez2, Elena Garmendia Sánchez1, Susana Gil2, Ana Ruibal-Escribano4, Margarida Vasques Rocha2, Francisco García Llorente5, César Antonio Egües6, Edurne Guerrero7 and Jaime Calvo-Alén2, 1Hospital Universitario Cruces, Barakaldo, Spain, 2Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, 3Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, 4Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, 5Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, 6Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, 7Hospital Alto Deba, Arrasate, Pais Vasco, Spain

    Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
  • Abstract Number: 1625 • ACR Convergence 2020

    Pneumocystis Jiroveci Pneumonia in Immunocompromised Patients with Rheumatologic Disease in a Single, Tertiary Medical Center

    Zahra Rehman1, Megan Krause1, Jessica Newman2 and Pooja Bhadbhade1, 1The University of Kansas Medical Center, Kansas City, KS, 2The University of Kansas Medical Center, Kansas City

    Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is rare, but can be fatal among immunocompromised. There is no consensus on indications for PJP prophylaxis in rheumatologic patients.…
  • Abstract Number: 0455 • ACR Convergence 2020

    HLA-B27 and Host Immune Response: Lessons from Reactive Arthritis

    Sophie Wojcik1, Davina Morris2, Gillian Fitzgerald3, Steve Ramkissoon4, Nigil Haroon2 and Robert Inman5, 1UHN, Montreal, QC, Canada, 2University of Toronto, Toronto, ON, Canada, 3Toronto Western Hospital, Toronto, ON, Canada, 4UHN, Toronto, ON, Canada, 5University Health Network, Toronto, ON, Canada

    Background/Purpose: The natural history of reactive arthritis (ReA) remains poorly understood. Certain patients with ReA will go on to develop a chronic course while others…
  • Abstract Number: 0771 • ACR Convergence 2020

    Factors Associated to Clinical and Radiographic Disease Progression in Patients with Early RA and First-degree Relatives: A 1-year Follow-up

    Consuelo Romero-Sanchez1, Juan Manuel Bello-Gualtero2, Juliette De Avila3, Gloria Lafaurie4, Philipe Chalem Choueka5, Cesar Pacheco Tena6, Sebastian Giraldo-Q7, Jeimmy Andrea Chaparro-Sanabria8, Alejandro Ramos-Casallas3, Lorena Chila-M3 and Wilson Bautista-Molano9, 1Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, 2Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, 3Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, 4Universidad El Bosque, Basic Oral Research Unit – UIBO, School of Dentistry, Bogotá D.C., Colombia, 5Fundacion Instituto de Reumatología Fernando Chalem, Universidad El Rosario, Bogotá D.C., Colombia, 6Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico, 7Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogota D.C., Colombia, 8Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, 9University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia

    Background/Purpose: In rheumatoid arthritis (RA), autoimmunity towards citrullinated peptides driven the hypothesis, in which periodontal disease (PD) is strongly related to the pathogenesis. Given the…
  • Abstract Number: 1685 • ACR Convergence 2020

    Impact of the COVID-19 Pandemic Among Children with Rheumatic Diseases from Around the Globe

    Jonathan Hausmann1, Kevin Kennedy2, Salman Surangiwala3, Maggie Larche4, Karen Durrant5, Rashmi Sinha6 and Emily Sirotich4, 1Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 2McMaster University, Hamilton, Canada, 3Queen’s School of Medicine, Kingston, Canada, 4McMaster University, Hamilton, ON, Canada, 5Autoinflammatory Alliance, San Francisco, CA, 6SJIA Foundation, Cincinnati

    Background/Purpose: Children with rheumatic diseases face unknown risks in the setting of the COVID-19 pandemic.  These children are often immunosuppressed due to their underlying disease…
  • Abstract Number: 0002 • ACR Convergence 2020

    Hydroxychloroquine and Chloroquine and Hospitalizations for Viral Infection in the Pre-COVID-19 Era

    Cristiano Moura1, Marina Machado1, Celline Almeida-Brasil1, Jeffrey R Curtis2, Kevin Winthrop3, Michal Abrahamowicz1 and Sasha Bernatsky4, 1McGill University, Montreal, Canada, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Oregon Health & Science University, Portland, OR, 4The Research Institute of the McGill University Health Centre, Montreal, ON, Canada

    Background/Purpose: Chloroquine (CQ) and hydroxychloroquine (HCQ) have been shown to have antiviral properties and were considered as potential therapeutic options amid the COVID-19 pandemic. The…
  • Abstract Number: 0456 • ACR Convergence 2020

    Reduced Risk of Serious Pneumococcal Infection up to 10 Years After Immunization with 7-valent Conjugated Pneumococcal Vaccine in Patients with Inflammatory Arthritis

    Johanna Nagel1, Göran Jönsson2, Jan Åke Nilsson3, Chanchai Manuswin4, Martin Englund5, Tore Saxne1, Pierre Geborek1 and Meliha Kapetanovic1, 1Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, 2Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden, Lund, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, 4Centre of Registers South, Skåne University Hospital, Lund, Sweden, Lund, Sweden, 5Lund University, Lund, Sweden

    Background/Purpose: The aim was to examine the rates of putative pneumococcal infections up to 10 years before and after administration of heptavalent conjugated pneumococcal vaccine…
  • Abstract Number: 0776 • ACR Convergence 2020

    The Influence of Adipokine Profile and Periodontal Infection in Early Stages of Rheumatoid Arthritis and First-degree Relatives

    Consuelo Romero-Sanchez1, Juliette De Avila2, Jeimmy Andrea Chaparro-Sanabria3, Philipe Chalem Choueka4, Juan Manuel Bello-Gualtero5, Alejandro Ramos-Casallas2, Lorena Chila-M2 and Wilson Bautista-Molano6, 1Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, 2Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, 3Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, 4Fundacion Instituto de Reumatología Fernando Chalem, Universidad El Rosario, Bogotá D.C., Colombia, 5Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, 6University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia

    Background/Purpose: Early RA (eRA) patients have a significant incidence of periodontal inflammation and overweight/obesity. A similar degree of disease activity, functional disability and health-related quality…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology